ArticleHuman vaccines & immunotherapeutics2024

Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvant.

Marcus Estrada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.